German biotechnology company ProBioGen has collaborated with Austrian-based enzyme engineering firm Eucodis Bioscience to commercialise antibody drug conjugation (ADC) technology, C-LiNK (CTAT).
As per the agreed terms, ProBioGen will have exclusive rights to commercialise Eucodis’ enzymatic C-terminal linking technology, and to offer it, together with its antibody development services, royalty-free to ADC-developing parties.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
ProBioGen CEO Dr. Wieland Wolf said: "This agreement is an excellent match between Eucodis’ enzyme engineering expertise and ProBioGen’s therapeutic protein-optimising technologies and we look much forward to position C-LiNK and our contract manufacturing services right in the middle of the hot ADC field."
C-LiNK has the ability to covalently link toxins, drugs, or other substances to the C-terminus of an antibody or a recombinant protein, by a one-step enzymatic reaction.
The C-LiNK enzyme targets a short recognition sequence of 3-4 amino acids fused to the C-terminus of the to-be-conjugated protein. It then cleaves this specific sequence and covalently links the drug molecule to the antibody by a transamidation reaction, the company said.
The ADC technology enables adjusting a defined drug-antibody ratio (DAR) and, by modifying the linker, attaching more than one drug per site, or inserting a specific cleavage site, if needed.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataC-LiNK for ADC creation is either available as separate, royalty-free licence through ProBioGen or in combination with cell line development and manufacturing packages.
ProBioGen chief scientific officer Dr. Volker Sandig said: "This innovative ADC technology, which efficiently attaches any payload enzymatically via a pure peptide linker, as short as two amino acids, blends perfectly into our portfolio of robust cell line / product engineering technologies and manufacturing capabilities.
"The 1-step C-LiNK coupling technology will further open up the development space for ADCs and represents a competitive alternative to other Antibody Drug Conjugate Technologies."
